Invention Grant
- Patent Title: Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
-
Application No.: US15501760Application Date: 2015-08-07
-
Publication No.: US11219672B2Publication Date: 2022-01-11
- Inventor: Haruki Okamura , Kyosuke Yamanishi , Wen Li
- Applicant: Haruki Okamura , Kyosuke Yamanishi , Yoshimasa Tanaka , MEDICAL RESEARCH AND DEVELOPMENT CORPORATION , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
- Applicant Address: JP Osaka; JP Hyogo; JP Nagasaki; JP Aichi; JP Hyogo
- Assignee: Haruki Okamura,Kyosuke Yamanishi,Yoshimasa Tanaka,MEDICAL RESEARCH AND DEVELOPMENT CORPORATION,FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
- Current Assignee: Haruki Okamura,Kyosuke Yamanishi,Yoshimasa Tanaka,MEDICAL RESEARCH AND DEVELOPMENT CORPORATION,FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
- Current Assignee Address: JP Osaka; JP Hyogo; JP Nagasaki; JP Aichi; JP Hyogo
- Agency: Casimir Jones, S.C.
- Agent Tanya A. Arenson
- International Application: PCT/JP2015/072505 WO 20150807
- International Announcement: WO2016/021720 WO 20160211
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K38/00 ; A61K39/395 ; A61K38/20 ; C07K16/24 ; C07K16/28
Abstract:
A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.
Public/Granted literature
- US20170224791A1 THERAPEUTIC AGENT FOR CANCER WHICH COMPRISES COMBINATION OF IL-18 AND MOLECULE-TARGETING ANTIBODY Public/Granted day:2017-08-10
Information query
